These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 22198801)

  • 41. Disease-modifying drugs in Alzheimer's disease.
    Ghezzi L; Scarpini E; Galimberti D
    Drug Des Devel Ther; 2013 Dec; 7():1471-8. PubMed ID: 24353405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Strategy and perspectives for development of Alzheimer disease-modifying drugs].
    Yanagisawa K
    Seishin Shinkeigaku Zasshi; 2012; 114(3):262-7. PubMed ID: 22568060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.
    Muñoz-Torrero D
    Curr Med Chem; 2008; 15(24):2433-55. PubMed ID: 18855672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Alzheimer's disease: current status and new perspectives.
    Scarpini E; Scheltens P; Feldman H
    Lancet Neurol; 2003 Sep; 2(9):539-47. PubMed ID: 12941576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.
    Zhang F; Zhong RJ; Cheng C; Li S; Le WD
    Acta Pharmacol Sin; 2021 Sep; 42(9):1382-1389. PubMed ID: 33268824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Old and new acetylcholinesterase inhibitors for Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1181-7. PubMed ID: 27459153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Anticholinesterases in the treatment of Alzheimer's disease].
    Gandía L; Alvarez RM; Hernández-Guijo JM; González-Rubio JM; de Pascual R; Rojo J; Tapia L
    Rev Neurol; 2006 Apr 16-30; 42(8):471-7. PubMed ID: 16625509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?
    Francis PT; Nordberg A; Arnold SE
    Trends Pharmacol Sci; 2005 Feb; 26(2):104-11. PubMed ID: 15681028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.
    Fisher A
    Neurotherapeutics; 2008 Jul; 5(3):433-42. PubMed ID: 18625455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carbamate as a potential anti-Alzheimer's pharmacophore: A review.
    Singh YP; Kumar N; Chauhan BS; Garg P
    Drug Dev Res; 2023 Dec; 84(8):1624-1651. PubMed ID: 37694498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current Strategies and Novel Drug Approaches for Alzheimer Disease.
    Ghai R; Nagarajan K; Arora M; Grover P; Ali N; Kapoor G
    CNS Neurol Disord Drug Targets; 2020; 19(9):676-690. PubMed ID: 32679025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
    Marucci G; Buccioni M; Ben DD; Lambertucci C; Volpini R; Amenta F
    Neuropharmacology; 2021 Jun; 190():108352. PubMed ID: 33035532
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of drugs for Alzheimer's disease.
    Sun X; Jin L; Ling P
    Drug Discov Ther; 2012 Dec; 6(6):285-90. PubMed ID: 23337815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer's disease.
    Silva CFM; Pinto DCGA; Silva AMS
    Expert Opin Drug Discov; 2018 Dec; 13(12):1141-1151. PubMed ID: 30430870
    [No Abstract]   [Full Text] [Related]  

  • 55. An update on drug treatment options of Alzheimer's disease.
    Allgaier M; Allgaier C
    Front Biosci (Landmark Ed); 2014 Jun; 19(8):1345-54. PubMed ID: 24896354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review.
    Campos C; Rocha NB; Vieira RT; Rocha SA; Telles-Correia D; Paes F; Yuan T; Nardi AE; Arias-Carrión O; Machado S; Caixeta L
    Psychiatr Danub; 2016 Mar; 28(1):2-12. PubMed ID: 26938815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent Progress in the Pharmacotherapy of Alzheimer's Disease.
    Khoury R; Patel K; Gold J; Hinds S; Grossberg GT
    Drugs Aging; 2017 Nov; 34(11):811-820. PubMed ID: 29116600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug candidates in clinical trials for Alzheimer's disease.
    Hung SY; Fu WM
    J Biomed Sci; 2017 Jul; 24(1):47. PubMed ID: 28720101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease.
    Lin CH; Huang YJ; Lin CJ; Lane HY; Tsai GE
    Curr Pharm Des; 2014; 20(32):5169-79. PubMed ID: 24410566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.
    Vallés AS; Borroni MV; Barrantes FJ
    CNS Drugs; 2014 Nov; 28(11):975-87. PubMed ID: 25248971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.